Aripiprazole in the treatment of Alzheimer's disease

Expert Opinion on Pharmacotherapy

Volumn 14, Issue 4, 2013, Pages 459-474

  De Deyn, Peter Paul ^a,b,c   Drenth, Annemieke F J ^a   Kremer, Berry P ^a   Oude Voshaar, Richard C ^a,d   Van Dam, Debby ^c  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b MIDDELHEIM HOSPITAL   (Belgium)

^c UNIVERSITY OF ANTWERP   (Belgium)

^d UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Alzheimer's disease; Aripiprazole; Atypical antipsychotics; BPSD; Dementia; NPS; Psychosis

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

ACCIDENTAL INJURY; AGITATION; AKATHISIA; ALZHEIMER DISEASE; ALZHEIMER DISEASE RELATED PSYCHOSIS; ANXIETY DISORDER; APATHY; ARTICLE; ASTHENIA; BRADYCARDIA; CEREBROSPINAL FLUID EXAMINATION; CEREBROVASCULAR DISEASE; COGNITIVE DEFECT; DELUSION; DEMENTIA; DEPRESSION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HALLUCINATION; HUMAN; HYPERACTIVITY; HYPERSALIVATION; LETHARGY; MEMORY; META ANALYSIS (TOPIC); MOTOR DYSFUNCTION; MUTATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; ORTHOSTATIC HYPOTENSION; PHASE 3 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PROLACTIN BLOOD LEVEL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEIZURE THRESHOLD; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; SPATIAL LEARNING; TACHYCARDIA; TARDIVE DYSKINESIA; TREMOR; WEIGHT GAIN;

ALZHEIMER DISEASE; ANTIPSYCHOTIC AGENTS; DOPAMINE AGONISTS; HUMANS; META-ANALYSIS AS TOPIC; OFF-LABEL USE; PIPERAZINES; PSYCHOTIC DISORDERS; QUINOLONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, DOPAMINE; SEROTONIN 5-HT2 RECEPTOR ANTAGONISTS;

EID: 84874467063     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2013.764989     Document Type: Article

References (127)

1. Sanford M, Keating GM. Aripiprazole: in adolescents with schizophrenia. Paediatr Drugs 2007;9(6):419-23
2. Stip E, Tourjman V. Aripiprazole in schizophrenia and schizoaffective disorder: a review. Clin Ther 2010;32(Suppl 1):S3-20
3. Croxtall JD. Aripiprazole: a review of its use in the management of schizophrenia in adults. CNS Drugs 2012;26(2):155-83
4. McIntyre RS. Aripiprazole for the maintenance treatment of bipolar I disorder: a review. Clin Ther 2010;32(Suppl 1):S32-8
5. McIntyre RS, Yoon J, Jerrell JM, Liauw SS. Aripiprazole for the maintenance treatment of bipolar disorder: a review of available evidence. Neuropsychiatr Dis Treat 2011;7:319-23
6. Blier P, Blondeau C. Neurobiological bases and clinical aspects of the use of aripiprazole in treatment-resistant major depressive disorder. J Affect Disord 2011;128(Suppl 1):S3-10
7. Pae CU, Forbes A, Patkar AA. Aripiprazole as adjunctive therapy for patients with major depressive disorder: overview and implications of clinical trial data. CNS Drugs 2011;25(2):109-27
8. Curran MP. Aripiprazole: in the treatment of irritability associated with autistic disorder in pediatric patients. Paediatr Drugs 2011;13(3):197-204
9. Farmer CA, Aman MG. Aripiprazole for the treatment of irritability associated with autism. Expert Opin Pharmacother 2011;12(4):635-40
10. Maher AR, Maglione M, Bagley S, et al. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. JAMA 2011;306(12):1359-69
11. Maher AR, Theodore G. Summary of the comparative effectiveness review on off-label use of atypical antipsychotics. J Manag Care Pharm 2012;18(5 Suppl B):1-20
12. Creese I, Burt DR, Snyder SH. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 1976;192(4238):481-3
13. Jaffe AB, Levine J. Efficacy and effectiveness of first-and second-generation antipsychotics in schizophrenia. J Clin Psychiatry 2003;64(Suppl 17):3-6
14. Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009;373(9657):31-41
15. Kuroki T, Nagao N, Nakahara T. Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin-dopamine hypothesis. Prog Brain Res 2008;172:199-212
16. Stahl SM. Describing an atypical antipsychotic: receptor binding and its role in pathophysiology. Prim Care Companion J Clin Psychiatry 2003;5:9-13
17. Lieberman JA. Dopamine partial agonists: a new class of antipsychotic. CNS Drugs 2004;18(4):251-67
18. Burris KD, Molski TF, Xu C, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 2002;302(1):381-9
19. Paulsen JS, Salmon DP, Thal LJ, et al. Incidence of and risk factors for hallucinations and delusions in patients with probable AD. Neurology 2000;54(10):1965-71
20. Eustace A, Coen R, Walsh C, et al. A longitudinal evaluation of behavioural and psychological symptoms of probable Alzheimer's disease. Int J Geriatr Psychiatry 2002;17(10):968-73
21. Devanand DP, Brockington CD, Moody BJ, et al. Behavioral syndromes in Alzheimer's disease. Int Psychogeriatr 1992;4(Suppl 2):161-84
22. Gilley DW, Whalen ME, Wilson RS, Bennett DA. Hallucinations and associated factors in Alzheimer's disease. J Neuropsychiatry Clin Neurosci 1991;3(4):371-6
23. Rabins PV, Mace NL, Lucas MJ. The impact of dementia on the family. JAMA 1982;248(3):333-5
24. Steele C, Rovner B, Chase GA, Folstein M. Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease. Am J Psychiatry 1990;147(8):1049-51
25. Doody RS, Stevens JC, Beck C, et al. Practice parameter: management of dementia (an evidence-based review). Report of the quality standards subcommittee of the American academy of neurology. Neurology 2001;56(9):1154-66
26. Kindermann SS, Dolder CR, Bailey A, et al. Pharmacological treatment of psychosis and agitation in elderly patients with dementia: four decades of experience. Drugs Aging 2002;19(4):257-76
27. Jeste DV, Blazer D, Casey D, et al. ACNP white paper: update on use of antipsychotic drugs in elderly persons with dementia. Neuropsychopharmacology 2008;33(5):957-70
28. Deaths with antipsychotics in elderly patients with behavioral disturbances. 2010.Available from: www.fda.gov/drugs/drugsafety/
29. Wang PS, Schneeweiss S, Avorn J, et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med 2005;353(22):2335-41
30. Schneeweiss S, Setoguchi S, Brookhart A, et al. Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. CMAJ 2007;176(5):627-32
31. Gill SS, Bronskill SE, Normand SL, et al. Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med 2007;146(11):775-86
32. Information for healthcare professionals-antipsychotics. 2011.Available from: www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafety InformationforPatientsand Providers/ucm124830.htm
33. Koopmans R, Wetzels R, Disselhorst L. Antipsychotics are sometimes useful in dementia. (Dutch). Medisch Contact 2012(29-30):1783-5
34. Liperoti R, Mor V, Lapane KL, et al. The use of atypical antipsychotics in nursing homes. J Clin Psychiatry 2003;64(9):1106-12
35. Briesacher BA, Limcangco MR, Simoni-Wastila L, et al. The quality of antipsychotic drug prescribing in nursing homes. Arch Intern Med 2005;165(11):1280-5
36. Bronskill SE, Anderson GM, Sykora K, et al. Neuroleptic drug therapy in older adults newly admitted to nursing homes: incidence, dose, and specialist contact. J Am Geriatr Soc 2004;52(5):749-55
37. Rochon PA, Stukel TA, Bronskill SE, et al. Variation in nursing home antipsychotic prescribing rates. Arch Intern Med 2007;167(7):676-83
38. Chen Y, Briesacher BA, Field TS, et al. Unexplained variation across US nursing homes in antipsychotic prescribing rates. Arch Intern Med 2010;170(1):89-95
39. Valiyeva E, Herrmann N, Rochon PA, et al. Effect of regulatory warnings on antipsychotic prescription rates among elderly patients with dementia: a population-based time-series analysis. CMAJ 2008;179(5):438-46
40. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (IV-TR). 4th edition. Text revised edition American Psychiatric Association; Washington DC: 2000
41. Henderson AS. Epidemiology of dementia disorders. Adv Neurol 1990;51:15-25
42. Wimo A, Winblad B, Aguero-Torres H, von Strauss E. The magnitude of dementia occurrence in the world. Alzheimer Dis Assoc Disord 2003;17(2):63-7
43. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzheimer's disease. Neurology 1984;34(7):939-44
44. Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007;6(8):734-46
45. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the national institute on aging-Alzheimer's association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7(3):263-9
46. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991;82(4):239-59
47. Pearson RC, Esiri MM, Hiorns RW, et al. Anatomical correlates of the distribution of the pathological changes in the neocortex in Alzheimer disease. Proc Natl Acad Sci USA 1985;82(13):4531-4
48. Scahill RI, Schott JM, Stevens JM, et al. Mapping the evolution of regional atrophy in Alzheimer's disease: unbiased analysis of fluid-registered serial MRI. Proc Natl Acad Sci USA 2002;99(7):4703-7
49. Coleman RE. Positron emission tomography diagnosis of Alzheimer's disease. Neuroimaging Clin N Am 2005;15(4):837; 46, x
50. Patwardhan MB, McCrory DC, Matchar DB, et al. Alzheimer disease: operating characteristics of PET-a meta-analysis. Radiology 2004;231(1):73-80
51. Motter R, Vigo-Pelfrey C, Kholodenko D, et al. Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol 1995;38(4):643-8
52. Vandermeeren M, Mercken M, Vanmechelen E, et al. Detection of tau proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay. J Neurochem 1993;61(5):1828-34
53. Bird TD. Genetic factors in Alzheimer's disease. N Engl J Med 2005;352(9):862-4
54. Finkel SI, Costa e Silva J, Cohen G, et al. Behavioral and psychological signs and symptoms of dementia: a consensus statement on current knowledge and implications for research and treatment. Int Psychogeriatr 1996;8(Suppl 3):497-500
55. Finkel S. Introduction to behavioural and psychological symptoms of dementia (BPSD). Int J Geriatr Psychiatry 2000;15(Suppl 1):S2-4
56. Finkel SI. Behavioral and psychological symptoms of dementia: a current focus for clinicians, researchers, and caregivers. J Clin Psychiatry 2001;62(Suppl 21):3-6
57. Aalten P, Verhey FR, Boziki M, et al. Neuropsychiatric syndromes in dementia. results from the European Alzheimer Disease Consortium. Part I. Dement Geriatr Cogn Disord 2007;24(6):457-63
58. Aalten P, Verhey FR, Boziki M, et al. Consistency of neuropsychiatric syndromes across dementias: results from the European Alzheimer Disease Consortium. Part II. Dement Geriatr Cogn Disord 2008;25(1):1-8
59. Lyketsos CG, Carrillo MC, Ryan JM, et al. Neuropsychiatric symptoms in Alzheimer's disease. Alzheimers Dement 2011;7(5):532-9
60. Jost BC, Grossberg GT. The evolution of psychiatric symptoms in Alzheimer's disease: a natural history study. J Am Geriatr Soc 1996;44(9):1078-81
61. Mega MS, Cummings JL, Fiorello T, Gornbein J. The spectrum of behavioral changes in Alzheimer's disease. Neurology 1996;46(1):130-5
62. Robert P, Onyike CU, Leentjens AF, et al. Proposed diagnostic criteria for apathy in Alzheimer's disease and other neuropsychiatric disorders. Eur Psychiatry 2009;24(2):98-104
63. Starkstein SE, Ingram L, Garau ML, Mizrahi R. On the overlap between apathy and depression in dementia. J Neurol Neurosurg Psychiatry 2005;76(8):1070-4
64. David R, Zeitzer J, Friedman L, et al. Non-pharmacologic management of sleep disturbance in Alzheimer's disease. J Nutr Health Aging 2010;14(3):203-6
65. Lee DR, Thomas AJ. Sleep in dementia and caregiving-assessment and treatment implications: a review. Int Psychogeriatr 2011;23(2):190-201
66. Jeste DV, Finkel SI. Psychosis of Alzheimer's disease and related dementias. Diagnostic criteria for a distinct syndrome. Am J Geriatr Psychiatry 2000;8(1):29-34
67. Schneider LS, Dagerman KS. Psychosis of Alzheimer's disease: clinical characteristics and history. J Psychiatr Res 2004;38(1):105-11
68. Ropacki SA, Jeste DV. Epidemiology of and risk factors for psychosis of Alzheimer's disease: a review of 55 studies published from 1990 to 2003. Am J Psychiatry 2005;162(11):2022-30
69. Gerdner LA, Swanson EA. Effects of individualized music on confused and agitated elderly patients. Arch Psychiatr Nurs 1993;7(5):284-91
70. Rowe M, Alfred D. The effectiveness of slow-stroke massage in diffusing agitated behaviors in individuals with Alzheimer's disease. J Gerontol Nurs 1999;25(6):22-34
71. Huybrechts KF, Gerhard T, Crystal S, et al. Differential risk of death in older residents in nursing homes prescribed specific antipsychotic drugs: population based cohort study. BMJ 2012;344:e977
72. Liperoti R, Onder G, Landi F, et al. All-cause mortality associated with atypical and conventional antipsychotics among nursing home residents with dementia: a retrospective cohort study. J Clin Psychiatry 2009;70(10):1340-7
73. Kikuchi T, Tottori K, Uwahodo Y, et al. 7-(4-[4-(2, 3-dichlorophenyl)-1- piperazinyl]butyloxy)-3, 4-dihydro-2(1H)-quinolinon e (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity. J Pharmacol Exp Ther 1995;274(1):329-36
74. Lawler CP, Prioleau C, Lewis MM, et al. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology 1999;20(6):612-27
75. Jordan S, Koprivica V, Chen R, et al. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol 2002;441(3):137-40
76. Bortolozzi A, Diaz-Mataix L, Toth M, et al. In vivo actions of aripiprazole on serotonergic and dopaminergic systems in rodent brain. Psychopharmacology (Berl) 2007;191(3):745-58
77. Goodnick PJ, Jerry JM. Aripiprazole: profile on efficacy and safety. Expert Opin Pharmacother 2002;3(12):1773-81
78. Bandelow B, Meier A. Aripiprazole, a "dopamine-serotonin system stabilizer" in the treatment of psychosis. German J Psychiatry 2003;6:9-13
79. Available from: http://www.druglib.com/druginfo/abilify/description- pharmacology/
80. Sparshatt A, Taylor D, Patel MX, Kapur S. A systematic review of aripiprazole-dose, plasma concentration, receptor occupancy, and response: implications for therapeutic drug monitoring. J Clin Psychiatry 2010;71(11):1447-56
81. Featherstone RE, Kapur S, Fletcher PJ. The amphetamine-induced sensitized state as a model of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2007;31(8):1556-71
82. Futamura T, Akiyama S, Sugino H, et al. Aripiprazole attenuates established behavioral sensitization induced by methamphetamine. Prog Neuropsychopharmacol Biol Psychiatry 2010;34(6):1115-19
83. Leite JV, Guimaraes FS, Moreira FA. Aripiprazole, an atypical antipsychotic, prevents the motor hyperactivity induced by psychotomimetics and psychostimulants in mice. Eur J Pharmacol 2008;578(2-3):222-7
84. Narita M, Takei D, Shiokawa M, et al. Suppression of dopamine-related side effects of morphine by aripiprazole, a dopamine system stabilizer. Eur J Pharmacol 2008;600(1-3):105-9
85. Nagai T, Murai R, Matsui K, et al. Aripiprazole ameliorates phencyclidine-induced impairment of recognition memory through dopamine D1 and serotonin 5-HT1A receptors. Psychopharmacology (Berl) 2009;202(1-3):315-28
86. Natesan S, Reckless GE, Nobrega JN, et al. Dissociation between in vivo occupancy and functional antagonism of dopamine D2 receptors: comparing aripiprazole to other antipsychotics in animal models. Neuropsychopharmacology 2006;31(9):1854-63
87. Schlumberger C, Pietraszek M, Gravius A, Danysz W. Effects of a positive allosteric modulator of mGluR5 ADX47273 on conditioned avoidance response and PCP-induced hyperlocomotion in the rat as models for schizophrenia. Pharmacol Biochem Behav 2010;95(1):23-30
88. Brennan JA, Graf R, Grauer SM, et al. WS-50030 [7-{4-[3-(1H-inden-3-yl) propyl]piperazin-1-yl}-1, 3-benzoxazol-2 (3H)-one]: a novel dopamine D2 receptor partial agonist/serotonin reuptake inhibitor with preclinical antipsychotic-like and antidepressant-like activity. J Pharmacol Exp Ther 2010;332(1):190-201
89. Nakai S, Hirose T, Mori T, et al. The effect of aripiprazole on prepulse inhibition of the startle response in normal and hyperdopaminergic states in rats. Int J Neurosci 2008;118(1):39-57
90. Nordquist RE, Risterucci C, Moreau JL, et al. Effects of aripiprazole/OPC-14597 on motor activity, pharmacological models of psychosis, and brain activity in rats. Neuropharmacology 2008;54(2):405-16
91. Arnt J. Pharmacological specificity of conditioned avoidance response inhibition in rats: inhibition by neuroleptics and correlation to dopamine receptor blockade. Acta Pharmacol Toxicol (Copenh) 1982;51(4):321-9
92. Oshibuchi H, Inada K, Sugawara H, Ishigooka J. Aripiprazole and haloperidol suppress excessive dopamine release in the amygdala in response to conditioned fear stress, but show contrasting effects on basal dopamine release in methamphetamine-sensitized rats. Eur J Pharmacol 2009;615(1-3):83-90
93. Russo E, Citraro R, Davoli A, et al. Ameliorating effects of aripiprazole on cognitive functions and depressive-like behavior in a genetic rat model of absence epilepsy and mild-depression comorbidity. Neuropharmacology 2012;64:371-9
94. Eren I, Naziroglu M, Demirdas A. Protective effects of lamotrigine, aripiprazole and escitalopram on depression-induced oxidative stress in rat brain. Neurochem Res 2007;32(7):1188-95
95. Burda K, Czubak A, Kus K, et al. Influence of aripiprazole on the antidepressant, anxiolytic and cognitive functions of rats. Pharmacol Rep 2011;63(4):898-907
96. Bourin M, Chenu F, Prica C, Hascoet M. Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice. Psychopharmacology (Berl) 2009;206(1):97-107
97. Kamei J, Miyata S, Sunohara T, et al. Potentiation of the antidepressant-like effect of fluoxetine by aripiprazole in the mouse tail suspension test. J Pharmacol Sci 2008;108(3):381-4
98. Biojone C, Casarotto PC, Resstel LB, et al. Anti-aversive effects of the atypical antipsychotic, aripiprazole, in animal models of anxiety. J Psychopharmacol 2011;25(6):801-7
99. Gaikwad U, Parle M. Combination of aripiprazole and ethanol attenuates marble-burying behavior in mice. Acta Pol Pharm 2011;68(3):435-40
100. Njung'e K, Handley SL. Evaluation of marble-burying behavior as a model of anxiety. Pharmacol Biochem Behav 1991;38(1):63-7
101. Gyertyan I. Analysis of the marble burying response: marbles serve to measure digging rather than evoke burying. Behav Pharmacol 1995;6(1):24-31
102. Bruins Slot LA, Bardin L, Auclair AL, et al. Effects of antipsychotics and reference monoaminergic ligands on marble burying behavior in mice. Behav Pharmacol 2008;19(2):145-52
103. Ishida T, Obara Y, Kamei C. Effects of some antipsychotics and a benzodiazepine hypnotic on the sleep-wake pattern in an animal model of schizophrenia. J Pharmacol Sci 2009;111(1):44-52
104. Shibasaki M, Kurokawa K, Mizuno K, Ohkuma S. Effect of aripiprazole on anxiety associated with ethanol physical dependence and on ethanol-induced place preference. J Pharmacol Sci 2012;118(2):215-24
105. Enomoto T, Ishibashi T, Tokuda K, et al. Lurasidone reverses MK-801-induced impairment of learning and memory in the Morris water maze and radial-arm maze tests in rats. Behav Brain Res 2008;186(2):197-207
106. Picada JN, Dos Santos Bde J, Celso F, et al. Neurobehavioral and genotoxic parameters of antipsychotic agent aripiprazole in mice. Acta Pharmacol Sin 2011;32(10):1225-32
107. Carli M, Calcagno E, Mainolfi P, et al. Effects of aripiprazole, olanzapine, and haloperidol in a model of cognitive deficit of schizophrenia in rats: relationship with glutamate release in the medial prefrontal cortex. Psychopharmacology (Berl) 2011;214(3):639-52
108. Ishiyama T, Tokuda K, Ishibashi T, et al. Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test. Eur J Pharmacol 2007;572(2-3):160-70
109. De Deyn PP, Jeste DV, et al. Aripiprazole for the treatment of psychosis in patients with Alzheimer's disease: a randomized, placebo-controlled study. J Clin Psychopharmacol 2005;25(5):463-7
110. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12(3):189-98
111. Cummings JL. The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. Neurology 1997;48(5 Suppl 6):S10-16
112. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep 1962;10:799-812
113. Guy W. Abnormal Involuntary Movement Scale (AIMS). In: ECDEU assessment manual for psychopharmacology. US Department of Health, Education, and Welfare publicaton (ADM); Rockville MD: 1976. p. 218-22
114. Mintzer JE, Tune LE, Breder CD, et al. Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: a multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses. Am J Geriatr Psychiatry 2007;15(11):918-31
115. Wood S, Cummings JL, Hsu MA, et al. The use of the Neuropsychiatric Inventory in nursing home residents. Characterization and measurement. Am J Geriatr Psychiatry 2000;8(1):75-83
116. Cohen-Mansfield J, Billig N. Agitated behaviors in the elderly. I. A conceptual review. J Am Geriatr Soc 1986;34(10):711-21
117. Cohen-Mansfield J. Assessment of disruptive behavior/agitation in the elderly: function, methods, and difficulties. J Geriatr Psychiatry Neurol 1995;8(1):52-60
118. Miller RJ, Snowdon J, Vaughan R. The use of the Cohen-Mansfield Agitation Inventory in the assessment of behavioral disorders in nursing homes. J Am Geriatr Soc 1995;43(5):546-9
119. Streim JE, Porsteinsson AP, Breder CD, et al. A randomized, double-blind, placebo-controlled study of aripiprazole for the treatment of psychosis in nursing home patients with Alzheimer disease. Am J Geriatr Psychiatry 2008;16(7):537-50
120. Alexopoulos GS, Abrams RC, Young RC, Shamoian CA. Cornell Scale for Depression in Dementia. Biol Psychiatry 1988;23(3):271-84
121. Rappaport SA, Marcus RN, Manos G, et al. A randomized, double-blind, placebo-controlled tolerability study of intramuscular aripiprazole in acutely agitated patients with Alzheimer's, vascular, or mixed dementia. J Am Med Dir Assoc 2009;10(1):21-7
122. Lindenmayer JP, Brown E, Baker RW, et al. An excitement subscale of the positive and negative syndrome scale. Schizophr Res 2004;68(2-3):331-7
123. Maher AR, Maglione M, Bagley S, et al. Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis. JAMA 2011;306(12):1359-69
124. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970;212:11-19
125. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry 1989;154:672-6
126. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 2005;294(15):1934-43
127. Kales HC, Valenstein M, Kim HM, et al. Mortality risk in patients with dementia treated with antipsychotics versus other psychiatric medications. Am J Psychiatry 2007;164(10):1568; 76; quiz 1623